BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Coherus BioSciences\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Coherus BioSciences\, Inc.'s drug
 s run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03859128-2018@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Toripalimab: Phase 2/3 readout est. (NCT03859128)
DESCRIPTION:Toripalimab\, phase 2/3.\nStudy: Toripalimab or Placebo as Adju
 vant Therapy in Hepatocellular Carcinoma After Radical Resection\nEstimate
 d primary completion: 31 December 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT03859128
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04523493-2018@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Toripalimab: Phase 3 readout est. (NCT04523493)
DESCRIPTION:Toripalimab\, phase 3.\nStudy: Phase III Study of Toripalimab
 （JS001） Combined With Lenvatinib for Advanced HCC\nEstimated primary c
 ompletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/toripalimab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04523493
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05180734-2018@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Toripalimab: Phase 3 readout est. (NCT05180734)
DESCRIPTION:Toripalimab\, phase 3.\nStudy: PD1 Combined With Chemotherapy f
 or Adjuvant Treatment of Gastric Cancer\nEstimated primary completion: 31 
 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripalim
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5180734
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04848753-2018@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270512
DTEND;VALUE=DATE:20270513
SUMMARY:Toripalimab: Phase 3 readout est. (NCT04848753)
DESCRIPTION:Toripalimab\, phase 3.\nStudy: Perioperative Toripalimab (JS001
 ) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Local
 ly Advanced Thoracic Esophageal Squamous Cell Carcinoma\nEstimated primary
  completion: 12 May 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/toripalimab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04848753
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05342194-2018@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Toripalimab: Phase 3 readout est. (NCT05342194)
DESCRIPTION:Toripalimab\, phase 3\, Cholangiocarcinoma.\nStudy: Toripalimab
  Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Adv
 anced ICC: a Phase III Study\nEstimated primary completion: 31 May 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05342194
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07484724-2018@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07484724)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: A Study Evaluating the Safety an
 d Efficacy of JS212 Combination Therapy in Patients With Advanced Esophage
 al Squamous Cell Carcinoma\nEstimated primary completion: 30 June 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07484724
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06095583-2018@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Toripalimab: Phase 3 readout est. (NCT06095583)
DESCRIPTION:Toripalimab\, phase 3.\nStudy: Phase 3 Study of Toripalimab Alo
 ne or in Combination With Tifcemalimab as Consolidation Therapy in Patient
 s With Limited-stage Small Cell Lung Cancer (LS-SCLC)\nEstimated primary c
 ompletion: 31 July 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/toripalimab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06095583
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07309276-2018@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07309276)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: A Phase II Clinical Study Evalua
 ting the Combination Therapy of JS212 in Patients With Advanced Lung Cance
 r\nEstimated primary completion: 30 November 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07309276
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07480733-2018@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07480733)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Phase II Study of JS212/JS213 as
  Monotherapy and in Combination in Patients With Advanced Malignant Solid 
 Tumors\nEstimated primary completion: 30 November 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07480733
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07876557-2018@assetmemo.bio
DTSTAMP:20261121T005021Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07876557)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: A Clinical Study to Evaluate the
  Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurr
 ent or Metastatic Triple-negative Breast Cancer(TNBC)\nEstimated primary c
 ompletion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/toripalimab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07876557
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
